-
International Dialogue | ASH President-Elect Prof. Robert Negrin Visits Yanda Ludaopei Hospital for a Deep-Dive Conversation with Prof. Lu Peihua on the Future of Cell Therapy
The completion and smooth relocation of the new Hebei Yanda Ludaopei Hospital campus mark a major step forward for the Ludaopei Medical Group’s clinical capacity. On this occasion, internationally renowned hematologist Professor Robert Negrin—Director of the Blood and Marrow Transplantation Program at Stanford University and President-Elect of the American Society of Hematology (ASH)—visited the hospital…
-
SUNMO Study: Mosunetuzumab + Polatuzumab Shows Breakthrough in DLBCL Treatment丨Professor Jason Weston
Treatment Dilemmas and the Emergence of Innovative Solutions For patients with relapsed or refractory large B-cell lymphoma (R/R LBCL) who are ineligible for curative treatments such as autologous stem cell…
-
POLARIX Trial: Pola-R-CHP Shows Clear Benefit in Specific DLBCL Subtypes丨Dr. Eleonora Calabretta on the Role of DLBclass
POLARIX Trial: Breaking the Two-Decade Standoff in First-Line DLBCL Treatment Over the past two decades, numerous clinical trials have attempted to improve the prognosis of DLBCL patients by adding new…
-
AZD0486 (Suvatomib) Shows Strong Efficacy and Safety in Relapsed/Refractory DLBCL丨Professor Maruyama on Latest Clinical Insights
Challenges in Relapsed/Refractory DLBCL Treatment and the Development Background of Suvatomib Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive non-Hodgkin lymphoma in adults. Although first-line chemoimmunotherapy regimens have…
-
CLL Breakthrough: BTK Degrader Bexobrutideg Shows Rapid, Durable Responses丨Professor Alexey Danilov on NX-5948
Mechanism of Action of Novel BTK Degrader Bexobrutideg and Unmet Needs Professor Alexey Danilov first introduced the mechanism of action of proteolysis-targeting chimeras (PROTACs) as a new class of drugs.…
-
EO2463 Peptide Immunotherapy Shows Promise in Follicular and Marginal Zone Lymphoma丨18-ICML
19- EO2463 Peptide Immunotherapy: Innovation Based on the Oncomimics Concept EO2463 is a “ready-to-use” peptide immunotherapy based on the “Oncomimics” concept, whose uniqueness lies in leveraging the host’s pre-existing immune…
-
New Era in Non-Hodgkin Lymphoma: Professor Franck Morschhauser on Breakthrough Phase I Results of a Novel BCL6 Degrader
Unmet Clinical Need: The Dilemma of Relapsed/Refractory Non-Hodgkin Lymphoma Relapsed/refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) remain challenging problems in the field of hematological oncology, especially for…
-
Extranodal Lymphoma Treatment Enters a New Era: IELSG’s 30-Year Journey of Academic Breakthroughs and Future Prospects丨Memorial Lecture
Legacy and Tribute Professor Emanuele Zucca. Since his graduation from the University of Milan in 1983, Professor Zucca has been dedicated to clinical research. With his profound expertise in clinical…
Connecting Medical Expertise through Media